首页> 外文期刊>Acta Cirurgica Brasileira >Analysis of gene expression EGFR and KRAS, microRNA-21 and microRNA-203 in patients with colon and rectal cancer and correlation with clinical outcome and prognostic factors 1
【24h】

Analysis of gene expression EGFR and KRAS, microRNA-21 and microRNA-203 in patients with colon and rectal cancer and correlation with clinical outcome and prognostic factors 1

机译:结肠癌和直肠癌患者的EGFR,KRAS,microRNA-21和microRNA-203基因表达分析及其与临床结局和预后因素的相关性1

获取原文
           

摘要

Purpose: To evaluate the expression of EGFR, KRAS genes, microRNAs-21 and 203 in colon and rectal cancer samples, correlated with their age at diagnosis, histological subtype, value of pretreatment CEA, TNM staging and clinical outcome. Methods: Expression of genes and microRNAs by real time PCR in tumor and non-tumor samples obtained from surgical treatment of 50 patients. Results: An increased expression of microRNAs-21 and 203 in tumor samples in relation to non-tumor samples was found. There was no statistically significant difference between the expression of these genes and microRNAs when compared to age at diagnosis and histological subtype. The EGFR gene showed higher expression in relation to the value of CEA diagnosis. The expression of microRNA-203 was progressively lower in relation to the TNM staging and was higher in the patient group in clinical remission. Conclusions: The therapy of colon and rectum tumors based on microRNAs remains under investigation reserving huge potential for future applications and clinical interventions in conjunction with existing therapies. We expect, based on the exposed data, to stimulate the development of new therapeutic possibilities, making the treatment of these tumors more effective.
机译:目的:评估结肠癌和直肠癌样品中EGFR,KRAS基因,microRNAs 21和203的表达,并与它们的诊断年龄,组织学亚型,治疗前CEA的价值,TNM分期和临床结果相关。方法:通过实时荧光定量PCR(RT-PCR)在50例患者的肿瘤和非肿瘤样品中表达基因和microRNA。结果:发现相对于非肿瘤样品,microRNAs-21和203在肿瘤样品中的表达增加。与诊断时的年龄和组织学亚型相比,这些基因和microRNA的表达在统计学上没有显着差异。 EGFR基因相对于CEA诊断价值显示出更高的表达。相对于TNM分期,microRNA-203的表达逐渐降低,在临床缓解期的患者组中较高。结论:基于microRNA的结肠和直肠肿瘤治疗仍在研究中,为与现有疗法结合的未来应用和临床干预提供巨大潜力。我们希望基于公开的数据刺激新的治疗方法的发展,从而使这些肿瘤的治疗更加有效。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号